 | Up a level |
Attard, Gerhardt; Murphy, Laura; Clarke, Noel W; Cross, William; Jones, Robert J; Parker, Christopher C; Gillessen, Silke; Cook, Adrian; Brawley, Chris; Amos, Claire L; Atako, Nafisah; Pugh, Cheryl; Buckner, Michelle; Chowdhury, Simon; Malik, Zafar; Russell, J Martin; Gilson, Clare; Rush, Hannah; Bowen, Jo; Lydon, Anna; ... (2022). Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. The lancet, 399(10323), pp. 447-460. Elsevier 10.1016/S0140-6736(21)02437-5
Hoyle, Alex P; Ali, Adnan; James, Nicholas D; Cook, Adrian; Parker, Christopher C; de Bono, Johann S; Attard, Gerhardt; Chowdhury, Simon; Cross, William R; Dearnaley, David P; Brawley, Christopher D; Gilson, Clare; Ingleby, Fiona; Gillessen, Silke; Aebersold, Daniel; Jones, Rob J; Matheson, David; Millman, Robin; Mason, Malcolm D; Ritchie, Alastair W S; ... (2019). Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. European urology, 76(6), pp. 719-728. Elsevier 10.1016/j.eururo.2019.08.006
Parker, Christopher C; James, Nicholas D; Brawley, Christopher D; Clarke, Noel W; Hoyle, Alex P; Ali, Adnan; Ritchie, Alastair W S; Attard, Gerhardt; Chowdhury, Simon; Cross, William; Dearnaley, David P; Gillessen, Silke; Gilson, Clare; Jones, Robert J; Langley, Ruth E; Malik, Zafar I; Mason, Malcolm D; Matheson, David; Millman, Robin; Russell, J Martin; ... (2018). Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet, 392(10162), pp. 2353-2366. Elsevier 10.1016/S0140-6736(18)32486-3
Mason, Malcolm D; Clarke, Noel W; James, Nicholas D; Dearnaley, David P; Spears, Melissa R; Ritchie, Alastair W S; Attard, Gerhardt; Cross, William; Jones, Rob J; Parker, Christopher C; Russell, J Martin; Thalmann, George; Schiavone, Francesca; Cassoly, Estelle; Matheson, David; Millman, Robin; Rentsch, Cyrill A; Barber, Jim; Gilson, Clare; Ibrahim, Azman; ... (2017). Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. Journal of clinical oncology, 35(14), pp. 1530-1541. American Society of Clinical Oncology 10.1200/JCO.2016.69.0677
James, Nicholas D; Sydes, Matthew R; Clarke, Noel W; Mason, Malcolm D; Dearnaley, David P; Spears, Melissa R; Ritchie, Alastair W S; Parker, Christopher C; Russell, J Martin; Attard, Gerhardt; de Bono, Johann; Cross, William; Jones, Rob J; Thalmann, George; Amos, Claire; Matheson, David; Millman, Robin; Alzouebi, Mymoona; Beesley, Sharon; Birtle, Alison J; ... (2016). Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, 387(10024), pp. 1163-1177. Elsevier 10.1016/S0140-6736(15)01037-5
James, Nicholas David; Spears, Melissa R; Clarke, Noel W; Dearnaley, David P; De Bono, Johann S; Gale, Joanna; Hetherington, John; Hoskin, Peter J; Jones, Robert J; Laing, Robert; Lester, Jason F; McLaren, Duncan; Parker, Christopher C; Parmar, Mahesh K B; Ritchie, Alastair W S; Russell, J Martin; Strebel, Räto T; Thalmann, George; Mason, Malcolm D and Sydes, Matthew R (2015). Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). European urology, 67(6), pp. 1028-1038. Elsevier 10.1016/j.eururo.2014.09.032
Attard, Gerhardt; Sydes, Matthew R; Mason, Malcolm D; Clarke, Noel W; Aebersold, Daniel; de Bono, Johann S; Dearnaley, David P; Parker, Chris C; Ritchie, Alastair W S; Russell, J Martin; Thalmann, George; Cassoly, Estelle; Millman, Robin; Matheson, David; Schiavone, Francesca; Spears, Melissa R; Parmar, Mahesh K B; James, Nicholas D (2014). Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. European urology, 66(5), pp. 799-802. Elsevier 10.1016/j.eururo.2014.05.038
James, Nicholas D; Sydes, Matthew R; Mason, Malcolm D; Clarke, Noel W; Anderson, John; Dearnaley, David P; Dwyer, John; Jovic, Gordana; Ritchie, Alastair W S; Russell, J Martin; Sanders, Karen; Thalmann, George N; Bertelli, Gianfilippo; Birtle, Alison J; O'Sullivan, Joe M; Protheroe, Andrew; Sheehan, Denise; Srihari, Narayanan; Parmar, Mahesh K B and STAMPEDE investigators, (2012). Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet oncology, 13(5), pp. 549-58. Oxford: Elsevier 10.1016/S1470-2045(12)70088-8
